Glucose dependent insulinotropic polypeptide and dipeptidyl peptidase inhibitors: Their roles in management of type 2 diabetes mellitus

Ankit Gupta; Hayder A Al-Aubaidy; Bassim I Mohammed

doi:10.1016/j.dsx.2016.03.013

Glucose dependent insulinotropic polypeptide and dipeptidyl peptidase inhibitors: Their roles in management of type 2 diabetes mellitus

Diabetes Metab Syndr. 2016 Apr-Jun;10(2 Suppl 1):S170-5. doi: 10.1016/j.dsx.2016.03.013. Epub 2016 Mar 14.

Authors

Ankit Gupta¹, Hayder A Al-Aubaidy², Bassim I Mohammed³

Affiliations

¹ School of Medicine, University of Tasmania, Hobart, Australia.
² School of Medicine, University of Tasmania, Hobart, Australia. Electronic address: H.AlAubaidy@utas.edu.au.
³ College of Pharmacy, Al-Qadisiya University, Iraq.

PMID: 27016884
DOI: 10.1016/j.dsx.2016.03.013

Abstract

This review paper highlights the major advances investigating the roles of glucose dependent insulinotropic polypeptide and its receptors in glucose metabolism and their potential use in management of type 2 diabetes mellitus. It also focusses on the role of dipeptidyl peptidase-4 inhibitors in the treatment of this disease. This study discussed the recent therapeutic development which have occurred in this field, and also covering the evolvement of the potential treatments for diabetes which can be discovered and implemented in the near future to design an effective therapy for diabetes and prediabetes.

Keywords: Dipeptidyl peptidase-4 inhibitors; Glucose dependent insulinotropic polypeptide; Type 2 diabetes mellitus.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
Gastric Inhibitory Polypeptide / therapeutic use*
Humans
Incretins / therapeutic use*
Models, Biological

Substances

Dipeptidyl-Peptidase IV Inhibitors
Incretins
Gastric Inhibitory Polypeptide